CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570)
Delenex is a biopharmaceutical company focused on the development of locally or topically applied antibody therapeutics. Thereby Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of patients. Delenex' prop...Show all
Company (Acquired)
Phone: +41-44-730 5180
Wagistrasse 27
Schlieren, CH-8952
Switzerland
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Antibodies against il-1 beta | Jun 16, 2015 | Mar 13, 2018 | Patent |
| Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase alk | Dec 16, 2014 | Dec 06, 2016 | Patent |
| Antibody to human il-1 beta | Nov 05, 2013 | Aug 02, 2016 | Patent |
| Humanized antibodies against the beta-amyloid peptide | Nov 02, 2012 | Mar 01, 2016 | Patent |
| Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase alk | Jan 31, 2011 | Feb 03, 2015 | Patent |
